Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 3, 2006, Pages 199-203

  Pönitz, Volker ^a,b   Pritchard, David ^c   Grundt, Heidi ^a,b   Nilsen, Dennis Winston T ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Axis Shield Diagnostics Ltd   (United Kingdom)

Author keywords

Fibrinolysis; Inflammation; Myocardial infarction; Thrombolysis; XIIa

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 12AA; BLOOD CLOTTING FACTOR 12AR; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TENECTEPLASE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; PRIORITY JOURNAL; SIDE EFFECT; ST SEGMENT ELEVATION;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33845246868     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-9031-6     Document Type: Article

References (23)

1. Silber S, Albertsson P, Aviles FF et al (2005) Guidelines for percutaneous coronary interventions, The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 26:804-847
2. Keeley EC, Boura JA, Grines CL et al (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 361:13-20
3. Merlini PA, Cugno M, Rossi ML et al (2004) Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 93:822-825
4. Hoffmeister HM, Szabo S, Helber U, Seipel L (2001) The thrombolytic paradox. Thromb Res 103:51-55
5. Szabo S, Letsch R, Ehlers R et al (2002) Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction. Comparison of single-bolus tenecteplase and front-loaded alteplase. Thromb Res 106:113-195
6. Latacha MP, Schaiff WT, Eisenberg PR, Abendschein DR (2004) FXII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis. J Thromb Haemost 2:128-134
7. Fujikawa K, McMullen BA (1983) Amino acid sequence of human β-factor XIIa. J Biol Chem 258:10924-10933
8. Mc Mullen BA, Fujikawa K (1985) Amino acid sequence of the heavy chain of human α-factor XIIa (activated Hageman factor). J Biol Chem 260:5328-5341
9. Pritchard D, Polwart R (2005) In-vivo, activated factor XII exists in multiple forms, but predominantly as a 53 kD Species. J Thromb Haemost Suppl.1:1821
10. Esnouf MP, Burgess AI, Dodds AW, Sarphie AF, Miller GJ (2000) A monoclonal antibody raised against human β-factor XIIa which also recognizes β-factor XIIa but not factor XII or complexes of factor XIIa with C1-esterase inhibitor. Thromb Haemost 83:874-881
11. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE (2004) Activated factor 12 (XIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 147:260-266
12. Cugno M, Cicardi M, Agostoni A (1994) Activation of the contact system and fibrinolysis in autoimmune aquired angioedema; a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 93:870-876
13. Agostoni A, Gardinali M, Frangi D et al (1994) Activation of the complement and kinin system after thrombolytic therapy in patients with acute myocardial infartion. Circulation 90:2666-2670
14. Hoffmeister HM, Szabo S, Kastner C et al (1998) Thrombolytic therapy in acute myocardial infarction: Comparison of procoagulant effect of streptokinase and alteplase regimen with focus on the kallikrein system, and plasmin. Circulation 98:2527-2533
15. Eisenberg PR, Sherman LA, Jaffe AD (1987) Paradoxic elevation of fibrinopeptide A after streptokinase; evidence for continued thrombosis despite fibrinolysis. J Am Coll Cardiol 10:527-529
16. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER (1988) Fibrinolytic therapy with tissue-type plasminogen activator or streptokinase induce transient thrombin activity. Blood 72:616-620
17. Merlini PA, Bauer KA, Oltrona L et al (1995) Thrombin generation and activity during thrombolysis and concominant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 25:203-208
18. Garabedian HD, Gold HK (1992) Coronary thrombolysis, conjunctive heparin infusion and the effect on systemic thrombin activity. Circulation 85:1205-1207
19. Pixley RA, Casselo A, De La Caneda RA, Kaufman N, Colman RW (1991) Effect of Heparin on the activation of Factor XII and the contact system in plasma. Thromb Haemaost 66:540-547
20. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE (1990) FXII. Blut 61:258-266
21. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens R (1984) In vitro activation of the contact (Hageman Factor) system of the plasma by heparin and chondroitin sulphate. E Blood 63:1453-1459
22. Pönitz V, Pritchard D, Grundt H, Mehus MB, Nilsen D (2005) Specific types of plasma activated Factor XII increase following percutaneous coronary intervention (PCI). J Thromb Haemost. Suppl 1:1736
23. Van de Werf F, Barron HV, Armstrong PV et al (2001) Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rt-PA. Eur Heart J 22:2221-2223